Company: ACBM
Filing Date: 2025-07-18
Form Type: 10-K
Source: 0001640334-25-001245
Chunk: 81

Company: ACRO BIOMEDICAL CO., LTD.
Filing Date: 2025-07-18
Form: 10-K
Item: Item 11
Chunk 81
---
000  $60,042  $32,293,530  $(23,773,383) $(7,936,482) $643,707                                  Amortization of deferred stock compensation   -   -   -   -   -   15,712,400   -   15,712,400 Imputed interest on related party loans  -   -   -   -   1,706   -   -   1,706 Net loss  -   -   -   -   -   -   (15,871,443)  (15,871,443)                                 Balance, December 31, 2022  -   -   60,042,000   60,042   32,295,236   (8,060,983)  (23,807,925)  486,370                                  Amortization of deferred stock compensation   -   -   -   -   -   8,060,983   -   8,060,983 Imputed interest on related party loans  -   -   -   -   3,206   -   -   3,206 Net loss  -   -   -   -   -   -   (8,807,573)  (8,807,573)                                 Balance, December 31, 2023  -  $-   60,042,000  $60,042  $32,298,442  $-  $(32,615,498) $(257,014)

The accompanying notes are an integral part of these financial statements.

 F-6Table of Contents

ACRO BIOMEDICAL CO., LTD.

Statements of Cash Flows

   Year Ended     December 31,    2023  2022        CASH FLOWS FROM OPERATING ACTIVITIES      Net loss $(8,807,573) $(15,871,443)Adjustments to reconcile net loss to net cash used in operating activities:        Imputed interest - related